Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-031 in infants with neonatal hypoxic-ischemic encephalopathy receiving hypothermia therapy
jRCT1080224818Phase 2Completed
- Sponsor
- JCR Pharmaceuticals
- Start
- Aug 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of remestemcel-L-rknd in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by JCR Pharmaceuticals. Started Aug 2019; status: completed.
02
Drugs
remestemcel-L-rknd
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on jRCT1080224818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224818.